Advances in First-Line Topical Therapies: The Role of a 2-Compound Ointment for Psoriasis Vulgaris

Mark G. Lebwohl, Linda Corvari, John Y. Koo, Steven R. Feldman, Joel M. Gelfand, Linda Stein Gold, Sherri D. Jones, Knud Kragballe, psoriasis vulgaris, 2-compound ointment, topical therapies, inflammation, corticosteroids, calcipotriene, chronic plaque-type, tazarotene, mometasone furoate, fluocinonide, betamethasone dipropionate, clobetasol, diflorasone diacetate, halobetasol propionate, calcipotriene, vitamin D, tacrolimus, alefacept, efalizumab, etanercept, infliximab, erythema, pruritis, burning

Mark G. Lebwohl, Linda Corvari, John Y. Koo, Steven R. Feldman, Joel M. Gelfand, Linda Stein Gold, Sherri D. Jones, Knud Kragballe, psoriasis vulgaris, 2-compound ointment, topical therapies, inflammation, corticosteroids, calcipotriene, chronic plaque-type, tazarotene, mometasone furoate, fluocinonide, betamethasone dipropionate, clobetasol, diflorasone diacetate, halobetasol propionate, calcipotriene, vitamin D, tacrolimus, alefacept, efalizumab, etanercept, infliximab, erythema, pruritis, burning

Mark G. Lebwohl, Linda Corvari, John Y. Koo, Steven R. Feldman, Joel M. Gelfand, Linda Stein Gold, Sherri D. Jones, Knud Kragballe, psoriasis vulgaris, 2-compound ointment, topical therapies, inflammation, corticosteroids, calcipotriene, chronic plaque-type, tazarotene, mometasone furoate, fluocinonide, betamethasone dipropionate, clobetasol, diflorasone diacetate, halobetasol propionate, calcipotriene, vitamin D, tacrolimus, alefacept, efalizumab, etanercept, infliximab, erythema, pruritis, burning